Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Loans - Net Loans - Net Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Accured Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Perspective Therapeutics (CATX) Goodwill (2023 - 2024)

Perspective Therapeutics' Goodwill history spans 2 years, with the latest figure at $24.1 million for Q3 2024.

On a quarterly basis, Goodwill fell 11.86% to $24.1 million in Q3 2024 year-over-year; TTM through Sep 2024 was $24.1 million, a 11.86% decrease, with the full-year FY2023 number at $24.1 million, changed N/A from a year prior.
Goodwill hit $24.1 million in Q3 2024 for Perspective Therapeutics, roughly flat from $24.1 million in the prior quarter.
Over the last five years, Goodwill for CATX hit a ceiling of $27.3 million in Q2 2023 and a floor of $24.1 million in Q4 2023.